vb-201
Small moleculeexperimental
Clinical trial activity
6 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
6
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2009 (NCT01001468)
Timeline
Indications
Mechanism of action
- Toll-like receptor 4INHIBITOR
TLR4 inhibitor
- Toll-like receptor 2INHIBITOR
Toll-like receptor 2 inhibitor
Monocyte differentiation antigen CD14 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CCCCCCCCCCCCCCCCOC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OCCCCC(=O)O- Mol. weight
- 581.77 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297333 ↗
Also known as
- vb-201
- vb-201
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04939311 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2022 | University of California, Los Angeles, University of California, San Francisco, University of Utah |
| NCT04733833 | Phase 2 | Jan 26, 2021 | VBL |
| NCT01839214 | Phase 2 | Jan 1, 2013 | VBL |
| NCT01837420 | Phase 2 | Nov 1, 2012 | VBL |
| NCT01159730 | Phase 2 | Oct 1, 2010 | VBL |
| NCT01001468 | Phase 2 | Dec 1, 2009 | VBL |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| VBL | For profit | 5 | 5 | 1 | 2009 |
| University of California, Los Angeles | Academic/Hospital | 1 | 0 | 1 | 2022 |
| University of California, San Francisco | Academic/Hospital | 1 | 1 | 1 | 2022 |
| University of Utah | Academic/Hospital | 1 | 0 | 1 | 2022 |
4 organizations
Page 1 / 1